Communiqués

13/08 PolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin EQ
20/07 PolyPeptide : Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share PU
20/07 PolyPeptide Group: Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share EQ
14/04 PolyPeptide Group AG takes note of market rumors and speculation EQ
08/04 PolyPeptide announces results of the annual General Meeting 2026 EQ
19/03 PolyPeptide strengthens financing structure through expansion of existing credit facility EQ
17/03 PolyPeptide publishes invitation to the annual General Meeting 2026 EQ
12/03 PolyPeptide : Media release (PolyPeptide FY 2025 Media release) PU
12/03 PolyPeptide : Full-year earnings presentation (PolyPeptide Group FY 2025 presentation) PU
12/03 PolyPeptide : Annual Report PU
12/03 PolyPeptide delivers strong revenue growth and marked improvement in profitability EQ
19/01 PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability EQ
12/12 PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies EQ
19/11 PolyPeptide : Jefferies London Healthcare Conference​, CEO presentation, November 2025 (20251119 PolyPeptide Jefferies London HC Conference) PU
28/10/25 Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market AQ
24/10/25 PolyPeptide : Capacity expansion underway at our Ambernath facility PU
22/09/25 PolyPeptide Group achieves significant milestone in Malmö expansion project EQ
01/09/25 Alzinova testimonial: Alzheimer’s peptide vaccine with PolyPeptide PU
12/08/25 PolyPeptide : Media release (English) (PolyPeptide H1 2025 Media release E FINAL ) PU
12/08/25 PolyPeptide : Half-year earnings presentation (PolyPeptide Group H1 2025 presentation) PU
12/08/25 PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range EQ
23/05/25 PolyPeptide announces expansion of existing credit facilities EQ
09/04/25 PolyPeptide announces results of the annual General Meeting 2025 EQ
18/03/25 PolyPeptide : publishes invitation to the annual General Meeting 2025 PU
18/03/25 PolyPeptide publishes invitation to the annual General Meeting 2025 EQ
Aucun résultat pour cette recherche